An Adaptive, Regimen Finding, Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-myeloablative Conditioning, for Tolerance Induction in Living Donor Renal Transplantation
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Siplizumab (Primary) ; Corticosteroid; Cyclophosphamide; Mycophenolate mofetil; Rituximab; Tacrolimus; Tocilizumab
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms PANORAMA
- Sponsors ITBMed Biopharmaceuticals
- 28 Oct 2022 Planned End Date changed from 1 Aug 2027 to 1 Jan 2030.
- 28 Oct 2022 Planned primary completion date changed from 1 Jul 2024 to 1 Jan 2027.
- 28 Oct 2022 Status changed from not yet recruiting to recruiting.